Compare ADMA Biologics Inc (ADMA) vs Canopy Growth Corp (CGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Canopy Growth Corp — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Canopy Growth Corp trades at $1 (market cap $421.10M). The key difference: ADMA Biologics Inc is far larger — about 5.3× Canopy Growth Corp's market cap. Which is the better fit depends on your goals.
| ADMA | CGC | |
|---|---|---|
Market Cap | $2.22B | $421.10M |
Sector | Health | Health |
52-Week High | $20.38 | $1.92 |
52-Week Low | $7.60 | $0.86 |
Enterprise Value | $2.29B | $378.55M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CGC trades at $0.95, down 1.86% in the last session, with a neutral technical signal and mixed analyst ratings (9 buy, 11 hold, 7 sell). The company reported Q1 2027 revenue growth of 13% year-over-year, beating estimates, but continues to post net losses. Recent news highlights expansion in European cannabis markets and cost-cutting efforts, while the stock remains volatile amid regulatory uncertainty.
Outlook is cautious due to persistent losses and high debt, though improving cash flow and revenue growth offer potential upside. Key risks include regulatory delays in U.S. cannabis rescheduling and competitive pressures. Investors should weigh the speculative nature against any positive regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
